BeiGene new flagship biologics manufacturing facility opens after $800M investment
The opening of BeiGene’s new flagship facility is the culmination of a three-year project to expand the company’s manufacturing and R&D in the US. The company invested $800 million to build the facilities, which house state-of-the-art biologics manufacturing capabilities and a clinical research and development center at the Princeton West Innovation Campus, which is located in Hopewell, New Jersey
Since its foundation in 2010, BeiGene has grown into a global company with a large oncology pipeline that aims to address 80% of the world’s cancers. The company currently has over 30 therapeutics at the clinical or commercial stage, including modalities such as antibody-drug conjugates (ADCs), targeted degraders, monoclonal antibodies and traditional small molecules among others.
The brand-new 42-acre facility will enable BeiGene to produce these innovative medicines at scale, reducing costs, ensuring supply chain resiliency and preventing global disruptions.The facility currently hosts 400,000 square feet dedicated to commercial-stage biologic pharmaceutical manufacturing, with space to expand capacity over time as BeiGene’s pipeline matures.
“BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients,” said John V. Oyler, co-founder, chairman and CEO of BeiGene.
“We are proud to be a part of New Jersey’s biopharmaceutical community that is rich in research and development and manufacturing talent. We look forward to deepening our relationships with key regional research institutions as we advance our robust pipeline of next-generation hematology and solid tumor medicines and continue to emerge as a leading global oncology innovator.”
BeiGene currently has over 10,0000 employees across five continents. With the opening of the new US flagship facility, the company expects to create hundreds of skilled, high-tech jobs by the end of 2025.
New Jersey is a hubspot for pharmaceutical R&D companies in the US, making it an attractive location for companies in the biopharmaceutical industry looking to expand their presence in the country.
“I am thrilled by BeiGene’s contribution to our state’s thriving biopharmaceutical sector,” said Governor Phil Murphy. “We look forward to the positive impact BeiGene will have on our economy and the advancements they will bring to cancer treatment. This significant investment highlights New Jersey’s role as a global leader in pharmaceutical manufacturing, research and development. We are proud to support BeiGene’s mission to develop affordable and accessible treatments for cancer patients worldwide.”
